FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication for nonalcoholic steatosis (NASH). Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.
What’s next in line for fatty liver disease? – NASH News
Madrigal Pharmaceuticals celebrates EMA’s validation of the Marketing Authorization Application for Resmetirom, a potential breakthrough therapy for NASH/MASH with liver fibrosis, while eagerly awaiting FDA’s decision, marking significant progress in the fight against liver-related mortality in Europe.
Congress looking to wrap up FY2024 spending bills as they look ahead to FY 2025 appropriations – Liver Health Policy Update
Congress continues to narrowly avert a government shutdown, most recently with yet another Continuing Resolution to extend government funding through later in March.
Navigating Liver Cancer Care – Liver Cancers News
Please join us on April 18 for a liver cancer care webinar open to patients, caregivers, and health care professionals. Experts will discuss topics relevant to the care and treatment of liver cancer and its symptoms so that patients and providers alike can make informed care decisions.
Rare Advocacy on Capitol Hill, in the White House, & Beyond! – Pediatric & Rare Liver Diseases News
In February, GLI raised awareness and amplified the patient voice in discussions about transitions in care for rare liver diseases. Here are a few highlights.